Literature DB >> 9446664

Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia.

B Gardie1, J M Cayuela, S Martini, F Sigaux.   

Abstract

We have previously shown that the disruption/deletion of the MTS(MTS1-MTS2) locus due to illegitimate V(D)J recombinase activity is a genetic event characteristic of T-cell acute lymphoblastic leukemia (T-ALL). Inactivation of the p16INK4a tumor suppressor protein, encoded by MTS1, is thought to be the major functional consequence of these chromosomal rearrangements. The two other cell cycle inhibitors encoded by genes identified in the locus (p19ARF by MTS1 and p15INK4b by MTS2), also represent possible candidates for inactivating events. By analyzing p16INK4a expression in three cases in which an identical 36-kb deletion had deleted MTS2 and disrupted the p19ARF, but spared the p16INK4a MTS1 encoding exons, we have excluded p16INK4a and pinpointed p19ARF and/or p15INK4b as the functional target(s) of this rearrangement. Moreover, by the study of the MTS genomic configuration of 149 rearranged alleles from a large series of T-ALL cases, we have shown that p19ARF encoding exons were always disrupted or deleted, whereas p16INK4a and p15INK4b encoding exons were spared in four and 21 cases, respectively. These results suggest that p19ARF may be targeted by the genetic events that occur in the MTS locus in the majority of T-ALLs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9446664

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.

Authors:  F Magdinier; A P Wolffe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

2.  Inhibition of T-cell acute lymphoblastic leukemia proliferation in vivo by re-expression of the p16INK4a tumor suppressor gene.

Authors:  K Schoppmeyer; P S Norris; M Haas
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

3.  ARF mutation accelerates pituitary tumor development in Rb+/- mice.

Authors:  Kenneth Y Tsai; David MacPherson; Douglas A Rubinson; Alexander Yu Nikitin; Roderick Bronson; Kim L Mercer; Denise Crowley; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-16       Impact factor: 11.205

4.  Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation.

Authors:  C T Nguyen; F A Gonzales; P A Jones
Journal:  Nucleic Acids Res       Date:  2001-11-15       Impact factor: 16.971

5.  INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene.

Authors:  M Pinyol; L Hernández; A Martínez; F Cobo; S Hernández; S Beà; A López-Guillermo; I Nayach; A Palacín; A Nadal; P L Fernández; E Montserrat; A Cardesa; E Campo
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

6.  The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts.

Authors:  R Fåhraeus; D P Lane
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

7.  Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis.

Authors:  Seema Paliwal; Sandhya Pande; Ramesh C Kovi; Norman E Sharpless; Nabeel Bardeesy; Steven R Grossman
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

8.  Immortalization of human mammary epithelial cells is associated with inactivation of the p14ARF-p53 pathway.

Authors:  Vladimir A Shamanin; Elliot J Androphy
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

Review 9.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

10.  p16INK4A tumor suppressor gene expression and CD3epsilon deficiency but not pre-TCR deficiency inhibit TAL1-linked T-lineage leukemogenesis.

Authors:  Magali Fasseu; Peter D Aplan; Martine Chopin; Nicolas Boissel; Jean-Christophe Bories; Jean Soulier; Harald von Boehmer; François Sigaux; Armelle Regnault
Journal:  Blood       Date:  2007-05-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.